Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 3
2015 2
2016 3
2017 11
2018 8
2019 8
2020 9
2021 11
2022 4
2023 7
2024 9
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D, Tournev IL, Taylor MS, Coelho T, Planté-Bordeneuve V, Berk JL, González-Duarte A, Gillmore JD, Low SC, Sekijima Y, Obici L, Chen C, Badri P, Arum SM, Vest J, Polydefkis M; HELIOS-A Collaborators. Adams D, et al. Amyloid. 2023 Mar;30(1):1-9. doi: 10.1080/13506129.2022.2091985. Epub 2022 Jul 23. Amyloid. 2023. PMID: 35875890 Free article. Clinical Trial.
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Adams D, et al. Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16. Lancet Neurol. 2021. PMID: 33212063 Free article. Clinical Trial.
Large-scale profiling of antibody reactivity to glycolipids in patients with Guillain-Barré syndrome.
Thomma RCM, Halstead SK, de Koning LC, Wiegers EJA, Gourlay DS, Tio-Gillen AP, van Rijs W, Andersen H, Antonini G, Arends S, Attarian S, Barroso FA, Bateman KJ, Benedetti L, Van den Bergh P, Bürmann J, Busby M, Casasnovas C, Dardiotis E, Davidson A, Feasby TE, Fehmi J, Galassi G, Garcia-Sobrino T, Granit V, Gutiérrez-Gutiérrez G, Hadden RDM, Harbo T, Hartung HP, Hasan I, Holt JKL, Islam Z, Karafiath S, Katzberg HD, Kolb N, Kusunoki S, Kuwabara S, Kuwahara M, Lehmann HC, Leonhard SE, Martín-Aguilar L, Monges S, Nobile-Orazio E, Pardo J, Pereon Y, Querol L, Reisin RC, Rinaldi S, Ripellino P, Roberts RC, Scheidegger O, Shahrizaila N, Sheikh KA, Silvestri NJ, Sindrup SH, Stein B, Tan CY, Tankisi H, Visser LH, Waheed W, Huizinga R, Jacobs BC, Willison HJ; IGOS consortium. Thomma RCM, et al. Brain. 2025 Nov 4;148(11):4000-4015. doi: 10.1093/brain/awaf102. Brain. 2025. PMID: 40096525 Free PMC article.
Electrophysiological Monitoring of Asymptomatic Transthyretin Mutation Carriers.
Berard N, Verschueren A, Fortanier E, Grapperon AM, Kouton L, Rebouh H, Gallard J, Salort-Campana E, Attarian S, Delmont E. Berard N, et al. Among authors: grapperon am. Muscle Nerve. 2025 Feb;71(2):208-215. doi: 10.1002/mus.28318. Epub 2024 Dec 12. Muscle Nerve. 2025. PMID: 39668650 Free PMC article.
Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88L265P and CXCR4 mutations and underlying haemopathy.
Guérémy A, Boucraut J, Boudjarane J, Grapperon AM, Fortanier E, Farnault L, Gabert J, Vely F, Lacroix R, Kouton L, Attarian S, Delmont E. Guérémy A, et al. Among authors: grapperon am. J Neurol. 2024 Mar;271(3):1320-1330. doi: 10.1007/s00415-023-12068-4. Epub 2023 Nov 18. J Neurol. 2024. PMID: 37979093 Free article.
The utility of motor unit number index: A systematic review.
Fatehi F, Grapperon AM, Fathi D, Delmont E, Attarian S. Fatehi F, et al. Among authors: grapperon am. Neurophysiol Clin. 2018 Oct;48(5):251-259. doi: 10.1016/j.neucli.2018.09.001. Epub 2018 Oct 2. Neurophysiol Clin. 2018. PMID: 30287192
Prevalence of SOD1 and C9orf72 Variants Among French ALS Population: The GENIALS Study.
Corcia P, Erazo D, Amador MDM, Beltran S, Bernard E, Blasco H, Boutoleau-Bretonniere C, Bruneteau G, Camdessanche JP, Camu W, Cassereau J, Choumert A, Codron P, Cintas P, De La Cruz E, Danel V, Desnuelle C, Eyraud N, Esselin F, Fauret AL, Lefilliatre M, Fleury MC, Genestet S, Grapperon AM, Guy N, Jacquin-Piques A, Beauvais K, Lautrette G, Le Masson G, Mathis S, Piegay AS, Pittion-Vouyovitch S, Sauleau P, Soriani MH, Vershueren A, Mouzat K, Guissart C, Couratier P, Vourc'h P. Corcia P, et al. Among authors: grapperon am. Eur J Neurol. 2025 Aug;32(8):e70302. doi: 10.1111/ene.70302. Eur J Neurol. 2025. PMID: 40751342 Free PMC article.
68 results